| |
|
|
|
|
|
 |
| |
|
¾Æ½ºÅä½Å´çÀÇÁ¤ ASTOSIN SUGAR COATED TAB.
|
|
Àü¹®ÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
654800980[A19900181]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2008.03.01)(ÇöÀç¾à°¡)
\29 ¿ø/1Á¤(2006.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
Èæ»öÀÇ ´çÀÇÁ¤ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
30Á¤, 100Á¤ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 100¹Ð¸®±×·¥ |
30 Á¤ |
º´ |
8806548009800 |
8806548009831 |
|
| 100¹Ð¸®±×·¥ |
100 Á¤ |
PTP |
8806548009800 |
8806548009824 |
|
| 100¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806548009800 |
8806548009817 |
|
|
| ÁÖ¼ººÐÄÚµå |
268500ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
õ½Ä, ±âħ, °¡·¡
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:268500ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
[TDM ´ë»ó¾à¹°] Anticonvulsants
Phenobarbital
À¯È¿Ç÷û³óµµ: 15~40 §¶/§¢
¼ºÀÎ1ȸ1Á¤,1ÀÏ 3-4ȸ ½ÄÈÄ º¹¿ë
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
Xanthine°è ¾à¹° ºÎÀÛ¿ë ±â¿Õ·ÂÀÚ |
| ½ÅÁßÅõ¿© |
- º»ÀÎ ¶Ç´Â ¾çÄ£,ÇüÁ¦ µîÀÌ µÎµå·¯±â,Á¢Ã˼ºÇǺο°,¾Ë·¹¸£±â¼º ºñ¿°,ÆíµÎÅë,À½½Ä¹° ¾Ë·¹¸£±â µîÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀ» °®°í ÀÖ´Â »ç¶÷
- Áö±Ý±îÁö ¾à¿¡ ÀÇÇØ ¾Ë·¹¸£±â Áõ»ó(¿¹:
¹ß¿,¹ßÁø,°üÀýÅë,°¡·Á¿òÁõ µî)À» ÀÏÀ¸Å² ÀÏÀÌ ÀÖ´Â »ç¶÷
- °£Àå,½ÅÀå °©»ó¼±Áúȯ,´ç´¢º´µî º´ÀÌ ÀÖ´Â »ç¶÷,¸öÀÌ ¾àÇÑ »ç¶÷,¶Ç´Â °í¿ÀÌ ÀÖ´Â »ç¶÷
- ½ÉÀå¿¡ Àå¾Ö°¡ ÀÖ´Â »ç¶÷,Ç÷¾ÐÀÌ ³ôÀº »ç¶÷,¶Ç´Â °í·ÉÀÚ(¿°»êÆä´ÒÇÁ·ÎÆÄ³î¾Æ¹Î,¿°»ê¸ÞÅå½ÃÆä³ª¹Î,¿°»ê¸ÞÄ¥¿¡Æäµå¸°,¿°»ê¿¡Æäµå¸°,¿°»ê½´µµ¿¡Æäµå¸°À» ÇÔÀ¯ÇÏ´Â Á¦Á¦)
- ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖ´Ù°í »ý°¢µÇ´Â ºÎÀÎ,¼öÀ¯ºÎ
- ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷
|
| ÀÌ»ó¹ÝÀÀ |
µÎÅë, ºÒ¸é, ºÒ¾È, ¾îÁö·¯¿ò, À̸í, ÁøÀü, ¸¶ºñ°¨, °æ·Ã, ¾È¸éÈ«Á¶, ½É°èÇ×Áø, ºó¸Æ, ºÎÁ¤¸Æ, °£±â´ÉÀÌ»ó, ºÎÁ¾, À§ÀåÀå¾Ö(ƯÈ÷ ±¸¿ª, ±¸Åä), Á¹À½
|
| »óÈ£ÀÛ¿ë |
- ´Ù¸¥ Å©»êƾ(Xanthine)°è ¾à¹° ¶Ç´Â ÁßÃ߽ŰæÈïºÐÁ¦¿Í º´¿ëÅõ¿©½Ã °úµµÇÑ ÁßÃ߽Űæ ÀÚ±ØÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ ¾à¹°µé°ú º´¿ëÇÏÁö ¾Ê´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
- ¿¡¸®½º·Î¸¶À̽Å,Æ®¸®¾Æ¼¼Æ¿¿Ã·¹¾Èµµ¸¶À̽Å,Æ®¸®¾Ï½Ã³î·Ð,½Ã¸ÞƼµò,¿¡³ì»ç½Å,½ÃÇÁ·ÎÇ÷ϻç½Å,Åä¼öÇ÷ϻç½Å,¿°»êƼŬ·ÎÇǵòµîÀÇ ¾à¹°°úÀÇ º´¿ëÅõ¿©¿¡ ÀÇÇØ ¾Æ¹Ì³ëÇʸ°ÀÇ Ç÷Áß³óµµ°¡ »ó½ÂÇÑ´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
- ´ÙÀ½ ¾àµé°ú µ¿½Ã¿¡ º¹¿ëÇÏÁö ¸» °Í
- ´Ù¸¥ ÁøÇذŴã¾à,Ç×È÷½ºÅ¸¹ÎÁ¦,ÁøÁ¤Á¦ µî
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
(phenobarbital; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Diphenhydramine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ephedrine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Phenobarbital¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Aminophylline¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Theophylline is structurally related to theobromine and caffeine. The precise mechanism of action of theophylline is not known.
Diphenhydramine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Ephedrine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Ephedrine is a sympathomimetic amine - that is, its principal mechanism of action relies on its direct and indirect actions on the adrenergic receptor system, which is part of the sympathetic nervous system. Ephedrine increases post-synaptic noradrenergic receptor activity by (weakly) directly activating post-synaptic α-receptors and β-receptors, but the bulk of its effect comes from the pre-synaptic neuron being unable to distinguish between real adrenaline or noradrenaline from ephedrine. The ephedrine, mixed with noradrenaline, is transported through the noradrenaline reuptake complex and packaged (along with real noradrenaline) into vesicles that reside at the terminal button of a nerve cell. Ephedrine's action as an agonist at most major noradrenaline receptors and its ability to increase the release of both dopamine and to a lesser extent, serotonin by the same mechanism is presumed to have a major role in its mechanism of action.
Papaverine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.
Phenobarbital¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.
|
| Pharmacology |
Aminophylline¿¡ ´ëÇÑ Pharmacology Á¤º¸ Aminophylline is the ethylenediamine salt of theophylline. Theophylline stimulates the CNS, skeletal muscles, and cardiac muscle. It relaxes certain smooth muscles in the bronchi, produces diuresis, and causes an increase in gastric secretion.
Diphenhydramine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
Papaverine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.
Phenobarbital¿¡ ´ëÇÑ Pharmacology Á¤º¸ Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).
|
| Metabolism |
Aminophylline¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Diphenhydramine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)Cytochrome P450 3A4 (CYP3A4)
Papaverine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Xanthine dehydrogenase/oxidase
Phenobarbital¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C19 (CYP2C19)
|
| Protein Binding |
Aminophylline¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 60%
Diphenhydramine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 98 to 99%
Papaverine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ ~90%
Phenobarbital¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 20 to 45%
|
| Half-life |
Aminophylline¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 7-9 hours
Diphenhydramine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-4 hours
Papaverine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.5-2 hours
Phenobarbital¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 53 to 118 hours (mean 79 hours)
|
| Absorption |
Aminophylline¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Diphenhydramine¿¡ ´ëÇÑ Absorption Á¤º¸ Quickly absorbed with maximum activity occurring in approximately one hour.
Papaverine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Phenobarbital¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.
|
| Pharmacokinetics |
Diphenhydramine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ°í ÁøÁ¤ È¿°ú : 1-3 ½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-7 ½Ã°£
- Èí¼ö : ÃÊȸÅë°úÈ¿°ú°¡ ÀÖ¾î¼ 40 - 60 % Á¤µµ°¡ Àü½Å¼øÈ¯À¸·Î µé¾î°¨
- ´ë»ç : ´ëºÎºÐ °£´ë»ç, ÀϺδ Æó¿Í ½ÅÀå¿¡¼µµ ´ë»ç
- ´Ü¹é°áÇÕ : 78%
- ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£
Papaverine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : °æ±¸ : ½Å¼Ó
- ´Ü¹é°áÇÕ : 90%
- ´ë»ç : °£¿¡¼ ½Å¼ÓÈ÷ ´ë»ç
- ¹Ý°¨±â : 0.5-1.5½Ã°£
- ¼Ò½Ç : ´¢¸¦ ÅëÇØ ÁÖ·Î ´ë»çü·Î ¹è¼³
PhenobarbitalÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- °æ±¸ :
- ¼ö¸éÈ¿°ú ¹ßÇö½Ã°£ : 20-60ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 6-10 ½Ã°£
- Á¤¸ÆÅõ¿© :
- ÀÛ¿ë¹ßÇö½Ã°£ : 5ºÐ À̳»
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 30ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-10 ½Ã°£
- Èí¼ö : °æ±¸ : 70-90%
- ´Ü¹é°áÇÕ : 20-45%, ½Å»ý¾Æ¿¡¼´Â °¨¼ÒµÊ
- ´ë»ç : °£¿¡¼ hydroxylationµÇ°í glucuronide Æ÷ÇÕµÊ
- ¹Ý°¨±â :
- ½Å»ý¾Æ : 45-500 ½Ã°£
- ¿µ¾Æ : 20-133 ½Ã°£
- ¼Ò¾Æ : 37-73 ½Ã°£
- ¼ºÀÎ : 53-140 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1-6 ½Ã°£ À̳»
- ¼Ò½Ç : 20-50%°¡ ¼Òº¯À¸·Î ¹Ìº¯È ¹è¼³µÊ
Ephedrine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- °æ±¸Åõ¿©½Ã
- ÀÛ¿ë¹ßÇö½Ã°£ : 0.25-1½Ã°£ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 3-6 ½Ã°£
- ºÐÆ÷ : ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ
- ´ë»ç : °£´ë»ç¸¦ °ÅÀÇ ¹ÞÁö ¾ÊÀ½
- ¹Ý°¨±â : 2.5-3.6 ½Ã°£
- ¼Ò½Ç : 24½Ã°£³»¿¡ Åõ¿©·®ÀÇ 60-77%°¡ ¹Ìº¯Èü·Î ´¢¸¦ ÅëÇØ ¹è¼³µÊ
AminophyllineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
1.ºÐÆ÷ Vd = 0.45L/kg
2.¸ðÀ¯·Î °ÅÀÇ Ç÷Áß³óµµ¿Í °°Àº Á¤µµ·Î ºÐÆ÷Çϸç Źݵµ Åë°ú
3.´ë»ç : °£¿¡¼ demethylation, oxidation
4.¹Ý°¨±â : ³ªÀÌ, °£ ±â´É, ½É ±â´É, Æó Áúȯ, Èí¿¬·Â¿¡ µû¶ó ¸Å¿ì ´Ù¾ç
¡á AminophyllineÀÇ ¹Ý°¨±â
|
ȯÀÚ±º |
¹Ý°¨±â(hr) |
|
½Å»ý¾Æ |
|
|
¹Ì¼÷¾Æ |
30 |
|
Á¤»óºÐ¸¸ |
24 |
|
¿µ¾Æ |
|
|
4-52ÁÖ |
4-30 |
|
¼Ò¾Æ/û¼Ò³â |
|
|
1-9¼¼ |
2-10 (Æò±Õ4) |
|
9-16¼¼ |
4-16 |
|
¼ºÀÎ |
|
|
ºñÈí¿¬ÀÚ |
|
|
Èí¿¬ÀÚ |
4.4 |
|
½ÉÁúȯ,°£ºÎÀü |
20-30 |
¡á AminophyllineÀÇ ¿ªµ¿ÇÐ/¾à·ÂÇÐ
|
Á¦Çü |
ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ |
Åõ¿© °£°Ý |
|
³ªÁ¤/½Ã·´ |
2½Ã°£ |
6½Ã°£ |
|
Àå¿ëÁ¤ |
5½Ã°£ |
12½Ã°£ |
|
ÃòÀ×Á¤ |
1-1.5½Ã°£ |
6½Ã°£ |
|
¼¹æÁ¤ |
4-7½Ã°£ |
12½Ã°£ |
|
ÁÖ»çÁ¦ |
30ºÐÀÌÇÏ |
|
5.¼Ò½Ç : ¼Òº¯
6.¼ºÀÎÀº 10%°¡ ¹Ìº¯Èü·Î ¹è¼³µÇ°í ½Å»ý¾Æ´Â ´õ ¸¹Àº ¾ç(50%±îÁö)ÀÌ ¹Ìº¯Èü·Î ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Aminophylline¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Diphenhydramine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic and renal
Papaverine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Phenobarbital¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic (mostly via CYP2C19).
|
| Toxicity |
Aminophylline¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Diphenhydramine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.
Papaverine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Phenobarbital¿¡ ´ëÇÑ Toxicity Á¤º¸ CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.
|
| Drug Interactions |
Aminophylline¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aciclovir Acyclovir increases the effect and toxicity of theophyllineAdenosine This xanthine decreases the effect of adenosineButabarbital The barbiturate decreases the effect of theophyllineButalbital The barbiturate decreases the effect of theophyllineDihydroquinidine barbiturate The barbiturate decreases the effect of theophyllineAtracurium Theophylline decreases the effect of muscle relaxantCarbamazepine Carbamazepine increases or decreases the effect of theophyllineCarteolol Antagonism of action and increased effect of theophyllineCimetidine Cimetidine increases the effect of theophyllineCiprofloxacin The quinolone increases the effect of theophyllineClarithromycin Clarithromycin increases the effect amd toxicity of theophyllineDisulfiram Disulfiram increases the effect and toxicity of theophyllineDoxacurium Theophylline decreases the effect of muscle relaxantEnoxacin The quinolone increases the effect of theophyllineErythromycin The macrolide increases the effect and toxicity of theophyllineEthinyl Estradiol The contraceptive increases the effect and toxicity of theophyllineEthotoin Decreased effect of both productsFluvoxamine Fluvoxamine increases the effect and toxicity of theophyllineFosphenytoin Decreased effect of both productsGallamine Triethiodide Theophylline decreases the effect of muscle relaxantGrepafloxacin The quinolone increases the effect of theophyllineHalothane Increased risk of cardiac arrhythmiaInterferon Alfa-2a, Recombinant Interferon increases the effect and toxicity of theophyllineInterferon Alfa-2b, Recombinant Interferon increases the effect and toxicity of theophyllineInterferon alfa-n1 Interferon increases the effect and toxicity of theophyllineIsoniazid Isoniazid increases the effect and toxicity of theophhyllineJosamycin The macrolide increases the effect and toxicity of theophyllineMephenytoin Decreased effect of both productsMethohexital The barbiturate decreases the effect of theophyllineMetocurine Theophylline decreases the effect of muscle relaxantMexiletine Mexiletine increases the effect and toxicity of theophyllineMivacurium Theophylline decreases the effect of muscle relaxantNadolol Antagonism of action and increased effect of theophyllineNorfloxacin The quinolone increases the effect of theophyllinePancuronium Theophylline decreases the effect of muscle relaxantPefloxacin The quinolone increases the effect of theophyllinePeginterferon alfa-2a Interferon increases the effect and toxicity of theophyllinePeginterferon alfa-2b Interferon increases the effect and toxicity of theophyllinePentobarbital The barbiturate decreases the effect of theophyllinePentoxifylline Pentoxyfylline increases the effect and toxicity of theophyllinePhenytoin Decreased effect of both productsPindolol Antagonism of action and increased effect of theophyllinePrimidone The barbiturate decreases the effect of theophyllinePropafenone Propafenone increases the effect of theophyllinePropranolol Antagonism of action and increased effect of theophyllineQuinidine barbiturate The barbiturate decreases the effect of theophyllineRifampin Rifampin decreases the effect of theophyllineRitonavir Ritonavir decreases the effect of theophyllineRofecoxib Rofecoxib increases the effect and toxicity of theophyllineSecobarbital The barbiturate decreases the effect of theophyllineSotalol Antagonism of action and increased effect of theophyllineSt. John's Wort St. John's Wort decreases the effect of theophyllineTacrine Tacrine increases the effect and toxicity of theophyllineTalbutal The barbiturate decreases the effect of theophyllineTerbinafine Terbinafine increases the effect and toxicity of theophyllineThiabendazole Thiabendazole increases the effect and toxicity of theophyllineTiclopidine Ticlopidine increases the effect and toxicity of theophyllineTimolol Antagonism of action and increased effect of theophyllineTubocurarine Theophylline decreases the effect of muscle relaxantVecuronium Theophylline decreases the effect of muscle relaxantZileuton Zileuton increases the effect and toxicity of theophyllineVerapamil Verapamil increases the effect of theophyllineAmobarbital The barbiturate decreases the effect of theophyllineAprobarbital The barbiturate decreases the effect of theophyllineButethal The barbiturate decreases the effect of theophyllineHeptabarbital The barbiturate decreases the effect of theophyllineHexobarbital The barbiturate decreases the effect of theophyllineLithium Theophylline decreases serum levels of lithiumMestranol The contraceptive increases the effect and toxicity of theophyllineMethylphenobarbital The barbiturate decreases the effect of theophyllinePenbutolol Antagonism of action and increased effect of theophyllinePhenobarbital The barbiturate decreases the effect of theophyllineTroleandomycin The macrolide increases the effect and toxicity of theophylline
Diphenhydramine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Atomoxetine The CYP2D6 inhibitor could increases the effect and toxicity of atomoxetineDonepezil Possible antagonism of actionGalantamine Possible antagonism of actionMesoridazine Increased risk of cardiotoxicity and arrhythmiasRivastigmine Possible antagonism of actionThioridazine Increased risk of cardiotoxicity and arrhythmias
Papaverine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Probenecid Probenecid increases the antibiotic's level
Phenobarbital¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aminophylline The barbiturate decreases the effect of theophyllineDyphylline The barbiturate decreases the effect of theophyllineOxtriphylline The barbiturate decreases the effect of theophyllineTheophylline The barbiturate decreases the effect of theophyllineAnisindione The barbiturate decreases the anticoagulant effectAcenocoumarol The barbiturate decreases the anticoagulant effectDicumarol The barbiturate decreases the anticoagulant effectWarfarin The barbiturate decreases the anticoagulant effectBetamethasone The barbiturate decreases the effect of the corticosteroidCortisone acetate The barbiturate decreases the effect of the corticosteroidCyclosporine The barbiturate decreases the effect of cyclosporineDasatinib Decreased levels/efficacy of ddasatinibDelavirdine The anticonvulsant decreases the effect of delavirdineDexamethasone The barbiturate decreases the effect of the corticosteroidDisopyramide Phenobarbital decreases levels of disopyramideDoxycycline The anticonvulsant decreases the effect of doxycyclineFelbamate Felbamate increases the effect and toxicity of phenobarbital/primidoneFelodipine The barbiturate decreases the effect of felodipineFludrocortisone The barbiturate decreases the effect of the corticosteroidFolic Acid Folic acid decreases the effect of anticonvulsantGefitinib This CYP3A4 inducer may reduce gefitinib plasma concentrations and pharmacological effectsGriseofulvin The barbiturate decreases the effect of griseofulvinHydrocortisone The barbiturate decreases the effect of the corticosteroidItraconazole The barbiturate decreases the effect of itraconazoleMethadone The barbiturate decreases the effect of methadoneMethylprednisolone The barbiturate decreases the effect of the corticosteroidPrednisolone The barbiturate decreases the effect of the corticosteroidPrednisone The barbiturate decreases the effect of the corticosteroidParamethasone The barbiturate decreases the effect of the corticosteroidTriamcinolone The barbiturate decreases the effect of the corticosteroidVoriconazole The barbiturate decreases the effect of voriconazoleVerapamil The barbiturate decreases the effect of the calcium channel blockerSunitinib Possible decrease in sunitinib levelsPropranolol The barbiturate decreases the effect of the metabolized beta-blockerMetoprolol The barbiturate decreases the effect of the metabolized beta-blockerMethoxyflurane The barbiturate increases the renal toxicity of methoxyfluraneMetronidazole The barbiturate decreases the effect of metronidazoleNifedipine The barbiturate decreases the effect of the calcium channel blockerQuinidine The anticonvulsant decreases the effect of quinidineDivalproex sodium Valproic acid increases the effect of barbiturateChlorotrianisene The enzyme inducer decreases the effect of hormonesClomifene The enzyme inducer decreases the effect of hormonesDiethylstilbestrol The enzyme inducer decreases the effect of hormonesEstradiol The enzyme inducer decreases the effect of hormonesEstriol The enzyme inducer decreases the effect of hormonesConjugated Estrogens The enzyme inducer decreases the effect of hormonesEstrone The enzyme inducer decreases the effect of hormonesEstropipate The enzyme inducer decreases the effect of hormonesImatinib Phenobarbital decreases levels of imatinibLevonorgestrel Phenobarbital decreases the effect of levonorgestrelMedroxyprogesterone The enzyme inducer decreases the effect of hormonesMegestrol The enzyme inducer decreases the effect of hormonesQuinestrol The enzyme inducer decreases the effect of hormonesNorethindrone This product may cause a slight decrease of contraceptive effectMestranol This product may cause a slight decrease of contraceptive effectEthinyl Estradiol This product may cause a slight decrease of contraceptive effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Phenobarbital¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2B6
bupropion
cyclophosphamide
efavirenz
ifosfamide
methadone
INHIBITORS
CYP 2B6
thiotepa
ticlopidine
INDUCERS
CYP 2B6
**phenobarbital**
phenytoin
rifampin
SUBSTRATES
CYP 3A4/3A5/3A7
Macrolide antibiotics:
clarithromycin
erythromycin
NOT azithromycin
telithromycin
Anti-arrhythmics:
quinidine
Benzodiazepines:
alprazolam
diazepam
midazolam
triazolam
Immune Modulators:
cyclosporine
tacrolimus (FK506)
HIV Protease Inhibitors:
indinavir
ritonavir
saquinavir
Prokinetic:
cisapride
Antihistamines:
astemizole
chlorpheniramine
Calcium Channel Blockers:
amlodipine
diltiazem
felodipine
nifedipine
nisoldipine
nitrendipine
verapamil
HMG CoA Reductase Inhibitors:
atorvastatin
cerivastatin
lovastatin
NOT pravastatin
simvastatin
aripiprazole
buspirone
gleevec
haloperidol (in part)
methadone
pimozide
quinine
NOT rosuvastatin
sildenafil
tamoxifen
trazodone
vincristine
INHIBITORS
CYP 3A4/3A5/3A7
HIV Protease Inhibitors:
indinavir
nelfinavir
ritonavir
amiodarone
NOT azithromycin
cimetidine
clarithromycin
diltiazem
erythromycin
fluvoxamine
grapefruit juice
itraconazole
ketoconazole
mibefradil
nefazodone
troleandomycin
verapamil
INDUCERS
CYP 3A4/3A5/3A7
carbamazepine
**phenobarbital**
phenytoin
rifabutin
rifampin
St. John's wort
troglitazone
|
| Food Interaction |
Aminophylline¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food.Limit caffeine intake.Vitamin B6 needs increased, supplement recommended.
Diphenhydramine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food.
Papaverine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
Phenobarbital¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Avoid excessive quantities of coffee or tea (Caffeine).Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.Take on an empty stomach for quicker absorption
|
| Drug Target |
[Drug Target]
|
| Description |
Aminophylline¿¡ ´ëÇÑ Description Á¤º¸ Aminophylline is a drug combination that contains theophylline and ethylenediamine in 2:1 ratio. [Wikipedia]
Diphenhydramine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
Ephedrine¿¡ ´ëÇÑ Description Á¤º¸ An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. [PubChem]
Papaverine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]
Phenobarbital¿¡ ´ëÇÑ Description Á¤º¸ A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. [PubChem]
|
| Dosage Form |
Aminophylline¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution IntravenousTablet OralTablet, extended release Oral
Diphenhydramine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralCream TopicalElixir OralLiquid IntramuscularLiquid IntravenousLiquid OralLozenge OralStrip OralSyrup OralTablet OralTablet, chewable Oral
Ephedrine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralLiquid IntramuscularLiquid IntravenousPowder OralSolution IntramuscularTablet Oral
Papaverine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid Intravenous
Phenobarbital¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Elixir OralSolution IntramuscularTablet Oral
|
| Drug Category |
Aminophylline¿¡ ´ëÇÑ Drug_Category Á¤º¸ Bronchodilator AgentsCardiotonic AgentsPhosphodiesterase InhibitorsRespiratory Smooth Muscle Relaxants
Diphenhydramine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Allergic AgentsAntidyskineticsAntiemeticsAntiparkinson AgentsAntipruriticsAntitussivesEthanolamine DerivativesHistamine H1 AntagonistsHypnotics and Sedatives
Ephedrine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic AgentsCentral Nervous System StimulantsSympathomimeticsVasoconstrictor Agents
Papaverine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Phosphodiesterase InhibitorsVasodilator Agents
Phenobarbital¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnticonvulsantsExcitatory Amino Acid AntagonistsGABA ModulatorsHypnotics and Sedatives
|
| Smiles String Canonical |
Aminophylline¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NCCN.CN1C(=O)N(C)C2=C(NC=N2)C1=O.CN1C(=O)N(C)C2=C(NC=N2)C1=O
Diphenhydramine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Ephedrine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CNC(C)C(O)C1=CC=CC=C1
Papaverine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Phenobarbital¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
|
| Smiles String Isomeric |
Aminophylline¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NCCN.CN1C(=O)N(C)C2=C(NC=N2)C1=O.CN1C(=O)N(C)C2=C(NC=N2)C1=O
Diphenhydramine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Ephedrine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN[C@@H](C)[C@H](O)C1=CC=CC=C1
Papaverine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Phenobarbital¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
|
| InChI Identifier |
Aminophylline¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2/f/h2*8H;
Diphenhydramine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
Ephedrine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
Papaverine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
Phenobarbital¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)/f/h13-14H
|
| Chemical IUPAC Name |
Aminophylline¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,3-dimethyl-7H-purine-2,6-dione; 1,3-dimethyl-7H-purine-2,6-dione; ethane-1,2-diamine
Diphenhydramine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[di(phenyl)methoxy]-N,N-dimethylethanamine
Ephedrine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1R,2S)-2-methylamino-1-phenylpropan-1-ol
Papaverine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
Phenobarbital¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|